When moderate-to-severe psoriasis patients were treated with IL-17A monoclonal antibody (secukinumab) for 52 weeks and then stopped the medication, 84% of patients experienced relapse of psoriasis within the next 52 weeks (8). This evidence concerns the gene IL17A and psoriasis.